SSY Group (HK:2005) has released an update.
SSY Group Limited has announced that it has received approval from China’s National Medical Products Administration for the production and registration of two new drugs: Norepinephrine Bitartrate Injection for blood pressure control in acute hypotensive conditions and Phloroglucinol Injection for treating various spasmodic pains. The company has made this voluntary announcement to inform shareholders and potential investors of the latest advancements in its product development.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
